CN102670624B - Patch for treating rheumatic arthritis and preparation method thereof - Google Patents
Patch for treating rheumatic arthritis and preparation method thereof Download PDFInfo
- Publication number
- CN102670624B CN102670624B CN201110061304.5A CN201110061304A CN102670624B CN 102670624 B CN102670624 B CN 102670624B CN 201110061304 A CN201110061304 A CN 201110061304A CN 102670624 B CN102670624 B CN 102670624B
- Authority
- CN
- China
- Prior art keywords
- patch
- chloroform
- preparation
- sensitive adhesive
- pressure sensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 201000003068 rheumatic fever Diseases 0.000 title abstract 5
- 239000003814 drug Substances 0.000 claims abstract description 22
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims abstract description 6
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims abstract description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 30
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 229920002367 Polyisobutene Polymers 0.000 claims description 15
- 229920002398 Oppanol® B Polymers 0.000 claims description 12
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 10
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000005030 aluminium foil Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 238000012946 outsourcing Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 17
- 230000000149 penetrating effect Effects 0.000 abstract description 6
- 239000000758 substrate Substances 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 229960004194 lidocaine Drugs 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003684 drug solvent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- -1 sugar alcohol fatty acid ester Chemical class 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N 1-dodecanol group Chemical group C(CCCCCCCCCCC)O LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 102100032373 Coiled-coil domain-containing protein 85B Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 101000868814 Homo sapiens Coiled-coil domain-containing protein 85B Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a patch for treating rheumatic arthritis and a preparation method thereof. The patch consists of a main medicament for treating rheumatic arthritis, a medicament solvent, a substrate and a penetrating agent, wherein the main medicament consists of triptolide and lidocaine serving as a pain-relieving medicament for relieving rheumatic arthritis pain. The patch is medical controlled-release slow release preparation, has a comprehensive pharmacological action, is used for blocking major development pathologic loops of the rheumatic arthritis disease, and has high specificity and a lasting pharmacological effect; and the preparation method is simple.
Description
Technical field
The present invention relates to field of pharmaceutical preparations and formulation method, especially relate to and a kind ofly treat rheumatoid arthritis patch having topical pain relief concurrently and preparation method thereof.
Background technology
Patch sticks the thin slice stratiform preparation in human body skin, and wherein percutaneous drug absorption enters the general designation of local target tissue or systemic circulation system, includes the patch of local skin transmission and transdermal delivery.Patch belongs to transdermal delivery system, is the pharmaceutical preparation with better usefulness row, and blood drug level can be kept to be stabilized in the Valid concentration for the treatment of; Owing to avoiding the first pass effect of drug oral through gastrointestinal tract and liver, more stably directly enter blood flow than oral administration, can improve medicine in vivo predictability; Improve safety; Improve the advantages such as the compliance of patient.
Radix Tripterygii Wilfordii lactone alcohol (triptolide) is the chemical composition extracted from Celastraceae tripterygium plant Radix Tripterygii Wilfordii.From pharmacological action: (1) Radix Tripterygii Wilfordii lactone alcohol had both had non-specific antiinflammatory immunity function, have again to suppress the immunization for main.(2) all there is obvious inhibitory action to Acute and chronic inflammation, and with hypophysis--system is relevant, mainly cause ACTH to discharge by hypophysis, adrenal cortex reinforcing secretory function.(3) research being applied to adjuvant arthritis shows: have obvious inhibitory action to rat assist agent arthritis, and rat assist agent arthritis is the animal model of research antirheumatic, and its histopathologic change is very similar to the rheumatoid arthritis of people.In a word, the pharmacological action of Radix Tripterygii Wilfordii lactone alcohol is comprehensive, just blocks the main pathology link of rheumatoid arthritis disease development, with strong points, evident in efficacy.It not only has the dual function of remission and disease amelioration concurrently, also there is the effect of parahormone sample and immunoregulation effect, but it is non-hormone again, multiple the acting on all over the body of collection multiclass medicine is that two class resisting rheumatoid arthritis Western medicine and amcinonide are incomparable.Lignocaine is widely used Bangesic clinically, can play the symptom of rheumatoid arthritis patient pain, alleviate the misery of patient.
At present, about the research report of patch and patent existing many, but not have for the patch of Radix Tripterygii Wilfordii lactone alcohol and lignocaine specially, therefore there is no its preparation method yet.
Summary of the invention
The object of the invention is to provide one to treat rheumatoid arthritis patch, and this patch is the slow releasing preparation of medicine controlled releasing, and principal agent can sustained release for a long time, and pharmacological effect is lasting, and formula is simple.
A kind of patch technologies scheme for the treatment of rheumatoid arthritis is:
One treats rheumatoid arthritis patch, principal agent wherein containing treatment rheumatoid arthritis, drug solvent, binding agent, patch substrate and Transdermal absorption penetrating agent, the principal agent for the treatment of rheumatoid arthritis is Radix Tripterygii Wilfordii lactone alcohol and the analgesic lidocaine hydrochloride alleviating rheumatoid arthritis pain, and the feature of this patch is the slow releasing preparation of medicine controlled releasing.
Described a kind of optimum weight proportioning for the treatment of each composition of rheumatoid arthritis patch is: principal agent (1): principal agent (2): Transdermal absorption penetrating agent: binding agent and patch substrate and solvent=0.1 ~ 1 ‰: 2 ‰: 1 ~ 10%: 65 ~ 95%.
The present invention also provides a kind of formula for the treatment of rheumatoid arthritis patch: Radix Tripterygii Wilfordii lactone alcohol (triptolide, triptolide) 481.5mg, lidocaine hydrochloride 2.4g, polyisobutylene oppanol B
10031.2g, polyisobutylene Oppanol B
1262.5g, lanoline 5.0g, liquid paraffin 15g, Borneolum Syntheticum 12g, 80% ethanol 9g, add chloroform to 1200g.
The present invention provides a kind of preparation method for the treatment of rheumatoid arthritis patch simultaneously, the first step: get high molecular weight polyisobutylene oppanol B
10031.2g and low-molecular-weight polyisobutylene Oppanol B
1262.5g, add chloroform to 1000g, until high and low molec weight polyisobutylene dissolves (pressure sensitive adhesive) for subsequent use completely. second step: dissolve Radix Tripterygii Wilfordii lactone alcohol with appropriate chloroform, dropwise slowly be added in 5g lanoline, limit edged stirs. the 3rd step: get 12g Borneolum Syntheticum and lidocaine hydrochloride 2.4g adds in beaker, dissolve with appropriate 80% ethanol and chloroform.4th step: the lanoline containing medicine is dropwise slowly added to limit edged in pressure sensitive adhesive and stirs.5th step: the dropwise containing 12g Borneolum Syntheticum and lidocaine hydrochloride is slowly added to limit edged in pressure sensitive adhesive and stirs, and add chloroform to 1200g.6th step: the pressure sensitive adhesive electric blender all having added medicine is stirred 1h, places 12h, then stirs 1h by electric blender, places 1-5h, to bubble-free, in impouring TB-300 type composite coating machine, is paved into the patch that thickness is 0.45mm.
Beneficial effect:
This patch:
(1) percutaneous drug absorption, directly enters body circulation, avoids medicine to be subject to liver sausage first-pass effect;
(2) not by the impact of gastrointestinal tract various factors, also directly stimulation or other adverse effect are not caused to gastrointestinal tract;
(3) this patch is the slow releasing preparation of medicine controlled releasing, has slow release long-acting feature, can reach 24 hours, and every day only need be administered once;
(4) extremely easy to use, without the need to oral or injection;
(5) safety, the toxic reaction of almost medication as none, particularly avoids the toxicity of Radix Tripterygii Wilfordii lactone alcohol;
(6) if in use there is untoward reaction, also can wipe immediately, stop administration.
This patch preparation method is simple, small investment, need not purchase main equipment and adopt complicated technique.
Detailed description of the invention
A kind of rheumatoid arthritis patch for the treatment of forms by treating the principal agent of rheumatoid arthritis, drug solvent, binding agent, substrate and Transdermal absorption penetrating agent, and principal agent is Radix Tripterygii Wilfordii lactone alcohol and the analgesic lidocaine hydrochloride alleviating rheumatoid arthritis pain.
Drug solvent is chloroform.
Binding agent and patch substrate are high molecular weight polyisobutylene oppanol B
100with low-molecular-weight polyisobutylene Oppanol B
12.
Transdermal absorption penetrating agent is lauryl alcohol, laurocapram (azone), Borneolum Syntheticum, Camphora, isopropyl myristate (IPM) wherein a kind or 2 kinds.
A kind of optimum weight proportioning for the treatment of each composition of rheumatoid arthritis patch is: principal agent (1): principal agent (2): Transdermal absorption penetrating agent: binding agent and patch substrate and solvent=0.1 ~ 1 ‰: 2 ‰: 1 ~ 10%: 65 ~ 95%.
A kind of formula for the treatment of rheumatoid arthritis patch is:
A kind of preparation method for the treatment of rheumatoid arthritis patch is: the preparation of (1) pressure sensitive adhesive: get high molecular weight polyisobutylene oppanol B
10031.2g and low-molecular-weight polyisobutylene Oppanol B
1262.5g, adds chloroform to 1000g, until high and low molec weight polyisobutylene dissolves for subsequent use completely.(2) dissolve Radix Tripterygii Wilfordii lactone alcohol with appropriate chloroform, be dropwise slowly added in 5g lanoline, limit edged stirs.(3) get 12g Borneolum Syntheticum and lidocaine hydrochloride 2.4g adds in beaker, dissolve with appropriate 80% ethanol and chloroform.(4) lanoline containing medicine is dropwise slowly added to limit edged in pressure sensitive adhesive to stir.(5) dropwise containing 12g Borneolum Syntheticum and lidocaine hydrochloride is slowly added to limit edged in pressure sensitive adhesive to stir, and adds chloroform to 1200g.(6) the pressure sensitive adhesive electric blender all having added medicine is stirred 1h, place 12h, then stir 1h by electric blender, place 1-5h, to bubble-free, in impouring TB-300 type composite coating machine, be paved into the patch that thickness is 0.45mm.
In the present invention, if necessary, suitably can also add and can be used for patch or operable additive, as PH regulators such as malic acid, phosphoric acid, citric acid, tartaric acid, lactic acid, diethanolamine, triethanolamine, diisopropanolamine (DIPA)s; The surfactant such as shrink pears sugar alcohol fatty acid ester, fatty acid glyceride, polyoxyethylene hydrogenation Semen Ricini, polyoxyethylene stearyl base ether, polyoxyethanyl lauryl ether, sodium lauryl sulfate; Lanoline, paraffin, olive pull oil, almond oil, polyisoprene, propylene glycol, colza wet goods softening agent; The astringent such as zinc oxide, aluminum sulfate; The antiseptic such as propyl p-hydroxybenzoate.
Patch of the present invention, can adopt the general method adopted in patch preparing technical field to prepare.
Special regulation is had to the container that dress patch uses: medicinal carton or medicinal plastic bag or aluminium foil bag in the present invention.
Claims (2)
1. treat a patch for rheumatoid arthritis, it is characterized in that: the formula of this patch is: triptolide 481.5mg, lidocaine hydrochloride 2.4g, polyisobutylene oppanol B
10031.2g, polyisobutylene oppanol B
1262.5g, lanoline 5g, Borneolum Syntheticum 12g, 80% ethanol 9g, add chloroform to 1200g.
2. treat a preparation method for rheumatoid arthritis patch as claimed in claim 1, it is characterized in that: the first step: get high molecular weight polyisobutylene oppanol B
10031.2g and polyisobutylene oppanol B
1262.5g, adds chloroform to 1000g, until high and low molec weight polyisobutylene dissolves completely, obtains pressure sensitive adhesive for subsequent use; Second step: dissolve triptolide with appropriate chloroform, be dropwise slowly added in 5g lanoline, limit edged stirs; 3rd step: get 12g Borneolum Syntheticum and lidocaine hydrochloride 2.4g adds in beaker, dissolves with appropriate 80% ethanol and chloroform; 4th step: the lanoline containing medicine is dropwise slowly added in pressure sensitive adhesive, limit edged stirs; 5th step: the dropwise containing Borneolum Syntheticum and lidocaine hydrochloride is slowly added to limit edged in pressure sensitive adhesive and stirs, and add chloroform to 1200g; 6th step: the pressure sensitive adhesive electric blender all having added medicine is stirred 1h, places 12 h, then stir 1h by electric blender, places 1-5h, to bubble-free, in impouring TB-300 type composite coating machine, is paved into the patch that thickness is 0.45mm;
Described patch is generally aluminium foil bag or plastic bag packaging, and outsourcing is carton.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110061304.5A CN102670624B (en) | 2011-03-14 | 2011-03-14 | Patch for treating rheumatic arthritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110061304.5A CN102670624B (en) | 2011-03-14 | 2011-03-14 | Patch for treating rheumatic arthritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102670624A CN102670624A (en) | 2012-09-19 |
| CN102670624B true CN102670624B (en) | 2015-04-15 |
Family
ID=46803615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110061304.5A Expired - Fee Related CN102670624B (en) | 2011-03-14 | 2011-03-14 | Patch for treating rheumatic arthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670624B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125733A (en) * | 2018-10-30 | 2019-01-04 | 成都先手生物科技有限公司 | A kind of composition for the treatment of of arthritis and its application |
| CN109908112B (en) * | 2019-04-19 | 2022-04-19 | 内蒙古科尔沁药业有限公司 | Non-allergic rubber plaster and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618030A (en) * | 2009-08-10 | 2010-01-06 | 沈阳亿灵医药科技有限公司 | Triptolide transdermal patch and preparation method thereof |
| CN102086199A (en) * | 2010-12-28 | 2011-06-08 | 广济药业（孟州）有限公司 | Method for self-extracting recycled riboflavin from liquid waste |
-
2011
- 2011-03-14 CN CN201110061304.5A patent/CN102670624B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101618030A (en) * | 2009-08-10 | 2010-01-06 | 沈阳亿灵医药科技有限公司 | Triptolide transdermal patch and preparation method thereof |
| CN102086199A (en) * | 2010-12-28 | 2011-06-08 | 广济药业（孟州）有限公司 | Method for self-extracting recycled riboflavin from liquid waste |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102670624A (en) | 2012-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016256818A1 (en) | Compositions and methods for tissue regeneration | |
| EP3275466A1 (en) | Diclofenac formulations | |
| Zhang et al. | Ionic liquids in transdermal drug delivery system: Current applications and future perspectives | |
| CN103239391B (en) | Tacrolimus ointment | |
| CN106620445B (en) | Skin-care microemulsion gel and preparation method thereof | |
| CN104688721A (en) | Anti-rheumatoid arthritis drug gel containing paclitaxel liposome and preparation method of gel | |
| CN101991585B (en) | Percutaneous absorption film coating agent for treating rheumatoid arthritis and preparation method thereof | |
| CN101417131B (en) | External medicine combination for treating skin allergic disease | |
| CN102133175B (en) | Amygdalin gel and preparation method and medicinal application thereof | |
| CN102670624B (en) | Patch for treating rheumatic arthritis and preparation method thereof | |
| WO2012099899A2 (en) | Topical dermatological compositions for the treatment of acne | |
| CN102085199B (en) | Percutaneous absorption biological patch for treating rheumatoid arthritis and preparing method thereof | |
| US10806790B1 (en) | Pain therapy cream with deep tissue delivery system | |
| CN104306447B (en) | A kind of pair of rattan micro emulsion gels and preparation method thereof | |
| CN101259149A (en) | Tinctura for treating beriberi | |
| KR102610339B1 (en) | Uses of Buliaconitin A | |
| CN104363915A (en) | Paralytic shellfish poison | |
| CN103181894A (en) | Nabumetone spraying agent and preparation method | |
| CN102423293B (en) | A kind of microemulsion gel preparation of oxiconazole nitrate | |
| CN103690473A (en) | Sinomenine preparation and preparation method thereof | |
| ES2394313T3 (en) | Transdermal formulation comprising an opioid analgesic and an aloe composition | |
| CN101284026B (en) | Chinese medicinal composition for treating skin hypersensitivity disease | |
| CN107929265A (en) | Preparation method of medicinal transdermal material | |
| CN100589805C (en) | External preparation of Levocetirizine hydrochloric acid | |
| CN102008536B (en) | Tripterygium wilfordii hook extract cataplasm and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150415 Termination date: 20200314 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |